LLF-KY Business Summary

LLF-KY (6666.TW) operates a vertically integrated beauty and wellness enterprise, generating revenue primarily through the wholesale distribution of high-end skincare products to a network of over 5,000 professional beauty salons across Mainland China. The company’s business model is structured around four strategic pillars: the core professional salon channel (B2B2C), the "Easy Bio" (伊姿佰) retail cosmetic store (CS) channel, a "Dual Beauty" medical aesthetics division comprising both flagship and community-based clinics, and a rapidly growing direct-to-consumer (DTC) e-commerce segment. Skincare products account for approximately 92% of total revenue, supported by proprietary R&D in bio-tech ingredients such as exosomes and red ball ginger. In the competitive landscape of the Greater China professional beauty market, LLF-KY competes directly with Chlitina Holding (4137.TW), Jourdeness (4190.TW), and Natural Beauty (0157.HK). The company maintains a premium market position by leveraging its "Medical + Beauty" integration and a science-backed product portfolio to capture high-lifetime-value customers in the mid-to-high-end segment. The leadership team is anchored by Founder and Chairperson Luo Li-Fen, a prominent figure in the Asian beauty industry with over four decades of experience who remains the group's strategic visionary. Executive management is led by General Manager Rao Huan-Wen, who oversees the company’s digital transformation and the expansion of its medical aesthetics footprint. The leadership group is supported by Assistant to the General Manager and Spokesperson Wang Zhi-Fu, who manages corporate communications and investor relations. Governance is characterized by strong family-led ownership, with major stakes held through investment vehicles such as Black Praise International and Talent Reach (HK) Limited. The board includes a mix of industry veterans and independent directors with expertise in pharmaceutical science and retail management, reflecting the company’s transition toward a technology-driven "Big Health" enterprise.